...
首页> 外文期刊>Biochimica et biophysica acta. Biomembranes >Insights into the molecular mechanism of action of Celastraceae sesquiterpenes as specific, non-transported inhibitors of human P-glycoprotein
【24h】

Insights into the molecular mechanism of action of Celastraceae sesquiterpenes as specific, non-transported inhibitors of human P-glycoprotein

机译:倍半萜烯作为人类P-糖蛋白的特异性非转运抑制剂的分子作用机理的见解

获取原文
获取原文并翻译 | 示例

摘要

Dihydro-beta-agarofuran sesquiterpenes from Celastraceae have been recently shown to bind to human P-glycoprotein (Pgp), functioning as specific, mixed-type inhibitors of its drug transport activity, as well as multidrug resistance (MDR) modulators in vitro. However, nothing is known about whether such compounds are themselves transported by Pgp, or whether they affect Pgp expression as well as its activity, or about the location of their binding site within the protein. We performed transport experiments with a newly synthesized fluorescent sesquiterpene derivative, which retains the anti-Pgp activity of its natural precursor. This probe was poorly transported by Pgp, MRP1, MRP2 and BCRP transporters, compared with classical MDR substrates. Moreover, Pgp did not confer cross-resistance to the most potent dihydro-beta-agarofurans, which did not affect Pgp expression levels in several MDR cell lines. Finally, we observed competitive and non-competitive interactions between one of such dihydro-beta-agarofurans (Mama12) and classical Pgp modulators such as cyclosporin A, verapamil, progesterone, vinblastine and GF120918. These findings suggest that multidrug ABC transporters do not confer resistance to dihydro-beta-agarofurans and could not affect their absorption and biodistribution in the body. Moreover, we mapped their binding site(s) within Pgp, which may prove useful for the rational design of improved modulators based on the structure of dihydro-beta-agarofurans. (c) 2005 Elsevier B.V. All rights reserved.
机译:最近显示,来自Celastraceae的二氢-β-agarofuran倍半萜烯与人P-糖蛋白(Pgp)结合,在其体外具有作为其药物转运活性的特异性,混合型抑制剂和多药耐药性(MDR)调节剂的功能。然而,关于这些化合物本身是否由Pgp转运,它们是否影响Pgp表达及其活性,或它们在蛋白质中的结合位点的位置,还不清楚。我们使用新合成的荧光倍半萜烯衍生物进行了运输实验,该衍生物保留了其天然前体的抗Pgp活性。与经典的MDR底物相比,该探针无法通过Pgp,MRP1,MRP2和BCRP转运蛋白转运。此外,Pgp没有赋予最有效的二氢-β-agarofuran交叉抗性,这不会影响几种MDR细胞系中Pgp的表达水平。最后,我们观察到了此类二氢-β-琼脂呋喃(Mama12)与经典Pgp调节剂(例如环孢菌素A,维拉帕米,孕酮,长春碱和GF120918)之间的竞争性和非竞争性相互作用。这些发现表明,多种药物的ABC转运蛋白不会赋予对二氢-β-琼脂糖呋喃的抗性,也不会影响它们在体内的吸收和生物分布。此外,我们在Pgp中绘制了它们的结合位点,这可能证明对基于二氢-β-琼脂糖呋喃结构的改良调节剂的合理设计有用。 (c)2005 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号